Literature DB >> 28319072

Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes.

R Martino1, A Henseler2, M van Lint3, N Schaap4, J Finke5, D Beelen6, S Vigouroux7, E P Alessandrino8, G J Mufti9, J H Veelken10, B Bruno11, I Yakoub-Agha12, L Volin13, J Maertens14, R Or15, V Leblond16, M Rovira17, P Kalhs18, A F Alvarez19, A Vitek20, J Sierra1, E Wagner21, M Robin22, T de Witte4, N Kröger23.   

Abstract

This study shows the long-term updated outcomes of a multicenter retrospective study which analyzed 843 patients with myelodysplastic syndrome (MDS) who underwent transplantation with an HLA-identical sibling donor with either reduced-intensity conditioning (RIC) in 213 patients, or standard myeloablative conditioning (MAC) in 630 patients. In multivariate analysis, the 13-year relapse rate was significantly increased after RIC (31% after MAC vs 48% in RIC; HR, 1.5; 95% CI, 1.1-1.9; P=0.04), but with no differences in overall survival (OS) (30% after MAC vs 27% in RIC; P=0.4) and PFS (29 vs 21%, respectively, P=0.3). Non-relapse mortality was higher in MAC (40 vs 31%; P=0.1), especially in patients older than 50 years (50 vs 33%, P<0.01). In addition, long-term follow-up confirms the importance of other variables on 13-year OS, mainly MDS risk category, disease phase, cytogenetics and receiving a high donor cell dose, irrespective of the conditioning regimen used.

Entities:  

Mesh:

Year:  2017        PMID: 28319072     DOI: 10.1038/bmt.2017.19

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  23 in total

1.  Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up.

Authors:  A Shimoni; I Hardan; N Shem-Tov; R Yerushalmi; A Nagler
Journal:  Leukemia       Date:  2010-02-11       Impact factor: 11.528

Review 2.  Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review.

Authors:  Simrit Parmar; Marcos de Lima; H Joachim Deeg; Richard Champlin
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

Review 3.  Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome.

Authors:  Nicolaus Kröger
Journal:  Blood       Date:  2012-04-13       Impact factor: 22.113

4.  Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity.

Authors:  J-H Lee; J-H Lee; S-N Lim; D-Y Kim; S H Kim; Y-S Lee; Y-A Kang; S-I Kang; M J Jeon; M Seol; E-J Seo; H S Chi; C J Park; S Jang; S-C Yun; K-H Lee
Journal:  Bone Marrow Transplant       Date:  2009-08-10       Impact factor: 5.483

5.  Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.

Authors:  John R Wingard; Navneet S Majhail; Ruta Brazauskas; Zhiwei Wang; Kathleen A Sobocinski; David Jacobsohn; Mohamed L Sorror; Mary M Horowitz; Brian Bolwell; J Douglas Rizzo; Gérard Socié
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

6.  Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.

Authors:  Matteo G Della Porta; Emilio Paolo Alessandrino; Andrea Bacigalupo; Maria Teresa van Lint; Luca Malcovati; Cristiana Pascutto; Michele Falda; Massimo Bernardi; Francesco Onida; Stefano Guidi; Anna Paola Iori; Raffaella Cerretti; Paola Marenco; Pietro Pioltelli; Emanuele Angelucci; Rosi Oneto; Francesco Ripamonti; Paolo Bernasconi; Alberto Bosi; Mario Cazzola; Alessandro Rambaldi
Journal:  Blood       Date:  2014-02-20       Impact factor: 22.113

7.  Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT.

Authors:  R Martino; L de Wreede; M Fiocco; A van Biezen; P A von dem Borne; R-M Hamladji; L Volin; M Bornhäuser; M Robin; V Rocha; T de Witte; N Kröger; M Mohty
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

8.  IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.

Authors:  Thomas J Nevill; John D Shepherd; Heather J Sutherland; Yasser R Abou Mourad; Julye C Lavoie; Michael J Barnett; Stephen H Nantel; Cynthia L Toze; Donna E Hogge; Donna L Forrest; Kevin W Song; Maryse M Power; Janet Y Nitta; Yunfeng Dai; Clayton A Smith
Journal:  Biol Blood Marrow Transplant       Date:  2009-02       Impact factor: 5.742

9.  Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome.

Authors:  Victoria T Potter; Pramila Krishnamurthy; Linda D Barber; Ziyi Lim; Michelle Kenyon; Robin M Ireland; Hugues de Lavallade; Abdel Dhouri; Judith C W Marsh; Robert Marcus; Stephen Devereux; Aloysius Ho; Antonio Pagliuca; Ghulam J Mufti
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-08       Impact factor: 5.742

10.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113

View more
  4 in total

1.  CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome .

Authors:  Pere Barba; Rodrigo Martino; Qin Zhou; Christina Cho; Hugo Castro-Malaspina; Sean Devlin; Albert Esquirol; Sergio Giralt; Ann A Jakubowski; Dolores Caballero; Molly Maloy; Esperanza B Papadopoulos; José Luís Piñana; María Laura Fox; Francisco J Márquez-Malaver; David Valcárcel; Carlos Solano; Lucía López-Corral; Jorge Sierra; Miguel-Angel Perales
Journal:  Biol Blood Marrow Transplant       Date:  2018-01-02       Impact factor: 5.742

2.  Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021?

Authors:  Nico Gagelmann; Nicolaus Kröger
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

3.  Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes.

Authors:  Betül Oran; Kwang Woo Ahn; Caitrin Fretham; Amer Beitinjaneh; Asad Bashey; Attaphol Pawarode; Baldeep Wirk; Bart L Scott; Bipin N Savani; Christopher Bredeson; Daniel Weisdorf; David I Marks; David Rizzieri; Edward Copelan; Gerhard C Hildebrandt; Gregory A Hale; Hemant S Murthy; Hillard M Lazarus; Jan Cerny; Jane L Liesveld; Jean A Yared; Jean Yves-Cahn; Jeffrey Szer; Leo F Verdonck; Mahmoud Aljurf; Marjolein van der Poel; Mark Litzow; Matt Kalaycio; Michael R Grunwald; Miguel Angel Diaz; Mitchell Sabloff; Mohamed A Kharfan-Dabaja; Navneet S Majhail; Nosha Farhadfar; Ran Reshef; Richard F Olsson; Robert Peter Gale; Ryotaro Nakamura; Sachiko Seo; Saurabh Chhabra; Shahrukh Hashmi; Shatha Farhan; Siddhartha Ganguly; Sunita Nathan; Taiga Nishihori; Tania Jain; Vaibhav Agrawal; Ulrike Bacher; Uday Popat; Wael Saber
Journal:  Transplant Cell Ther       Date:  2021-08-14

4.  Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?

Authors:  Gregory A Abel; Haesook T Kim; Andrew Hantel; David P Steensma; Richard Stone; Anand Habib; Vincent T Ho; Martha Wadleigh; Areej El-Jawahri; Edwin P Alyea; Daniel J DeAngelo; John Koreth; Joseph H Antin; Robert J Soiffer; Corey Cutler
Journal:  Leukemia       Date:  2020-11-17       Impact factor: 11.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.